(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed ...

A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care ...

A registration statement on Form S-1 (File No. 333-284225) relating to the offering has been filed with the Securities and Exchange Commission and became effective on January 30, 2025. The offering is ...

Impressive listing gains during the post-pandemic bull run have fueled investor confidence, prompting HNIs to allocate funds ...

Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that could make the kidney disease drug developer the first U.S. biotech ...

Smithfield Foods launched its initial public offering of stock this Tuesday (Jan. 28), selling 26 million shares at $20 each ...

Private equity-backed oil and natural gas producer Infinity Natural Resources on Thursday raised $265 million in its initial ...

Twin Peaks, a sports bar chain, made its debut on the Nasdaq Thursday, marking the first restaurant IPO of 2025.

Companies should not minimize the extent of a material cybersecurity incident by omitting material facts regarding the scope ...

Thursday marked the Nasdaq Global Market debut of Beta Bionics, Inc. as its initial public offering (IPO) opened for trading ...

Beta Bionics has announced the pricing of its upsized initial public offering of 12 million shares of common stock at a price to the public of $17 per share.

The lawyer behind a series of high-profile legal challenges to DEI practices is suing Bally’s and the city of Chicago over a $250 million IPO the suit says is unlawfully open only to people of color ...